Clopidogrel is a second-generation thienopyridine that blocks the adenosine diphosphate (ADP) P2Y 12 receptor antagonist. Following the results of the pivotal Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) trial [1] , it received approval from the Food and Drug Administration in 1997 and Conformité Européenne in 1998. Subsequent studies extend on the indications for its use in the setting of acute coronary syndromes (ACS) [2] , ST-segment elevation myocardial infarction [3, 4] and percutaneous coronary intervention (PCI) [5, 6] . Despite the robust clinical findings and indications for clopidogrel usage derived from these large-scale clinical trials performed over the course of the past decade, which are clearly reflected in clinical practice guidelines [7] [8] [9] , there are a large number of uncertainties regarding clopidogrel usage in daily real world practice. This is reflected by the plethora of publications dealing with clopidogrel over the course of the past several years. In a PubMed research, a total of 660 citations were identified from the years 2000-2005, which is almost sevenfold higher than that of the previous half-decade (1995) (1996) (1997) (1998) (1999) (2000) ; n = 96). Strikingly, from years 2006 to 2008, the number of clopidogrel related citations is 827 (Fig. 1) . It is quite certain that these figures will continue to increase over the course of the upcoming years with the introduction of novel antiplatelet agents that all have as their comparison agent clopidogrel, as this still represents the ADP P2Y 12 receptor antagonist of choice until new recommendations appear [10] .
In Internal and Emergency Medicine, Patti et al. [11] sought to address some of the most debated topics surrounding optimal clopidogrel usage, particularly in patients undergoing PCI. The authors address five issues regarding clopidogrel treatment strategies that are frequently encountered in daily clinical practice. The authors have addressed these aspects based on their accruing contribution to the scientific literature, having provided several landmark studies that have also set the basis for continuing research in the field. Therefore, the authors should not only be commended for their perspectives provided in this nicely done review article, but most importantly for their dedication to this important field of interventional pharmacology. Below we summarize the aspects addressed by Patti et al. in their review manuscript and provide our critical perspective.
The first question addressed is: Is early clopidogrel treatment needed in patients with ACS treated medically or undergoing PCI? The authors fully address this question by providing data from trials supporting early clopidogrel initiation in patients with ACS, either treated medically or undergoing coronary revascularization [4] [5] [6] . While there are no doubts on the clinical benefit achieved with clopidogrel pretreatment, a question that arises from this consideration is the timing necessary to achieve such a benefit. As highlighted in the manuscript by Patti et al. [11] , overall a long-pretreatment period (*12-15 h) is required to achieve clinical benefits when using a 300 mg loading dose, which is that approved by the FDA [12] . While high loading dose regimens (C600 mg) that accelerate platelet inhibitory processes may reduce this time frame, there is only limited data from small sample size studies on the clinical efficacy of this treatment strategy. In addition, despite the non-disputable clinical benefit achieved with clopidogrel pretreatment, many centers resist
Division of Cardiology, University of Florida College of Medicine-Jacksonville, 655 West 8th Street, Jacksonville, FL 32209, USA e-mail: dominick.angiolillo@jax.ufl.edu applying this strategy until coronary anatomy is known because of the irreversible effects of clopidogrel, which lead to delay (5-7 days) in case surgical revascularization is needed [7] . Indeed, the introduction of agents with reversible effects (e.g., ticagrelor, cangrelor, elinogrel) will be useful to overcome this limitation [10] .
The second question addressed is: What is the optimal clopidogrel loading dose in patients undergoing PCI? The authors have previously reported favorable outcomes with a 600-versus a 300-mg loading dose in patients undergoing PCI [13] . Other studies have confirmed these findings that are in line with the more rapid and potent effects of this dosing regimen, and which now represents the loading dose of choice by most interventionalists. Importantly, the updated PCI guidelines have recently provided a class I indication for a 600 mg dosing regimen, even though the data to support this are limited to relatively small samplesized studies [9] . It is for this reason that a 600 mg clopidogrel dose is not approved by regulatory authorities. The ongoing CURRENT/OASIS-7 (Clopidogrel optimal loading dose usage to reduce recurrent events/optimal antiplatelet strategy for interventions) trial (ClinicalTrials.gov identifier NCT00335452), currently being performed in *20,000 ACS patients with intent to undergo PCI, will provide the evidence to support if a 600 mg loading dose strategy is more effective, without safety concerns, compared to the approved 300 mg dose. It may be hypothesized that this aspect may lose some of its relevance with the introduction of new P2Y12 receptor antagonists, such as prasugrel (a third-generation thienopyridine), which has more prompt and potent antiplatelet effects even when compared to a 600 mg clopidogrel loading dose and associated with better clinical outcomes [14] .
The third question addressed is: In the context of a 600 mg loading strategy, is pre-treatment with clopidogrel before PCI needed, or can this loading dose be given in the catheterization laboratory, before intervention, but after coronary anatomy is known? In line with what has been described above (question one), the authors address this very important clinical question. Indeed, the authors have provided important preliminary findings attempting to address this topic [15] , which has only been approached in one other study [16] . While the authors provide their opinion as to which are the clinical scenarios in which a pre-treatment strategy can be omitted in favor of a 600 mg loading dose administered directly when coronary anatomy is known, we believe that larger scale studies are warranted to most adequately address this question. Indeed, as stated above, the introduction of novel P2Y 12 receptor inhibitors, which are characterized by more potent effects and many of which have reversible properties, will potentially represent important treatment alternatives to overcome this dilemma [10] .
The fourth question addressed is: What is the optimal clopidogrel strategy in patients on chronic clopidogrel therapy undergoing PCI? In clinical practice, a recurrent clinical question is how to manage clopidogrel treatment in patients already on maintenance therapy, who are admitted for an ACS or need to undergo PCI. Laboratory findings show that a reload with 600 mg of clopidogrel enhances platelet inhibition in these patients, suggesting that this may be potentially beneficial in clinical scenarios, such as ACS/PCI, where greater platelet inhibition is warranted [17] . In their manuscript, Patti et al. [11] report their preliminary findings, addressing the clinical impact of this reload strategy, and show a clinical benefit in ACS, but not in stable patients undergoing PCI. While these data provide some important insights into this topic, it is important to underscore that larger-scale study targeted on specific populations, rather than assumptions derived from subgroup analysis, are warranted to best address both the safety and efficacy of clopidogrel reloading. The fifth and last question addressed is: Does the degree of clopidogrel response influence the clinical outcome in patients undergoing PCI? Over the course of the past several years, there have been numerous studies evaluating the prognostic implications of clopidogrel response variability [18] . Nevertheless, there are numerous questions that surround this topic [19] . These include: which platelet function test should be used? What is the timing of testing? What are the cutoff values to define patients as poor responders? Which patient-population needs to be studied? What must be done for a poor responder? The latter represents the most important issue because based on the currently available data, it remains unclear if any modification in treatment is cost-effective [19] . Therefore, in line with expert consensus, at the current time, platelet function testing should be reserved for research purposes only.
In conclusion, clopidogrel has entered a phase in which many unsolved questions have been accumulating, and which are likely to increase with the introduction of novel antiplatelet agents currently under clinical development. A critical analysis of the evidence collected till now is always useful to consolidate the current knowledge and to identify cues for continuous research. Such critical appraisal may thus form the basis of dedicated outcome studies that will better direct our approach to patients and practice guidelines.
